ClinicalTrials.gg
CompletedNCT01026415Updated Dec 18, 2014

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

A Phase 1 interventional study of brentuximab vedotin and rifampin in Carcinomas, Disease, Hodgkin and Lymphoma, Large-Cell, Anaplastic, sponsored by Seagen Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Carcinoma by Pfizer — 6 open to participants now, 6 under way, 2 of them phase 3. Carcinoma · Pfizer.

Enrollment
15th of 24
73 · median 98
Started
2009
with 1 other
Phase 1
9 of 27
2 open now
Registered
17th of 27
by date

Among the 27 studies in Carcinoma by Pfizer, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2009, is one of 9 in phase 1, and was the 17th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

6 of the 27 studies in Carcinoma by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).

03

Conditions studied

  • Carcinomas
  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin
  • Neoplasms

Keywords

  • Antibody-Drug Conjugate
  • Antigens, CD30
  • Disease, Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • Lymphoma, Non-Hodgkin
  • monomethyl auristatin E
  • Drug Therapy
  • Immunotherapy
  • Hematologic Diseases
  • Lymphoma
  • Antibodies, Monoclonal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adequate organ function (Special Populations: serum >2 mg/dL or \<50 mL/min)
  • performance status \<2 (Special Populations: \<4)
  • CD30-positive

Exclusion criteria

Exclusion Criteria:

  • Receiving prohibited medication within 4 weeks
  • Poor liver function ( class C)
  • Current diagnosis of primary cutaneous ALCL
  • Acute or chronic
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    1

    midazolam +/- brentuximab vedotin

    Drug: brentuximab vedotin · Drug: midazolam

  • Experimental
    2

    brentuximab vedotin +/- rifampin

    Drug: brentuximab vedotin · Drug: rifampin

  • Experimental
    3

    brentuximab vedotin +/- ketoconazole

    Drug: ketoconazole · Drug: brentuximab vedotin

  • Experimental
    4

    special populations

    Drug: brentuximab vedotin

Interventions

  • 1.8 mg/kg IV every 21 days

    Also known as: ADCETRIS; SGN-35

  • Drugrifampin

    600 mg/day PO

  • Drugmidazolam

    1 mg IV

  • Drugketoconazole

    400 mg/day PO

  • 1.2 mg/kg IV every 21 days

    Also known as: SGN-35

06

What researchers measure

Primary outcomes

  1. Midazolam blood concentrations +/- brentuximab vedotin

    Time frame: 3 weeks

  2. Brentuximab vedotin blood concentrations +/- rifampin

    Time frame: 6 weeks

  3. Brentuximab vedotin in urine, feces, and blood

    Time frame: 1 week

  4. Brentuximab vedotin blood concentrations in special populations

    Time frame: 3 weeks

  5. Brentuximab vedotin blood concentrations +/- ketoconazole

    Time frame: 6 weeks

Secondary outcomes

  1. Incidence of adverse events and laboratory abnormalities

    Time frame: 6 weeks

07

Study locations

6 sites
  • City of Hope
    Duarte, California 91010, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • St. Francis Medical Group Oncology & Hematology Specialists
    Indianapolis, Indiana 46237, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48209, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Seattle Cancer Care Alliance / University of Washington Medical Center
    Seattle, Washington 98109-1023, United States
08

References and documents

Publications

  • Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O'Connor OA. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013 Aug;53(8):866-77. doi: 10.1002/jcph.116. Epub 2013 Jun 10. PubMed 23754575 ↗
  • Gopal AK, Ramchandren R, O'Connor OA, Berryman RB, Advani RH, Chen R, Smith SE, Cooper M, Rothe A, Matous JV, Grove LE, Zain J. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17. PubMed 22510871 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2009
First posted
Dec 4, 2009
Start
Dec 2009
Primary completionActual
May 2012
CompletionActual
May 2012
Last update
Dec 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01026415
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Dec 2009
Primary completion
May 2012
Completion
May 2012
Last update
Dec 18, 2014

Study contacts

Thomas Manley, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion